Narrowing the FOXF1 distant enhancer region on 16q24.1 critical for ACDMPV.

BACKGROUND: Alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) is a rare lethal lung developmental disorder caused by heterozygous point mutations or genomic deletions involving FOXF1 or its 60-kb tissue-specific enhancer region mapping 270 kb upstream of FOXF1 and involving fetal lung-expressed long non-coding RNA genes and CpG-enriched sites. Recently, we have proposed that the FOXF1 locus at 16q24.1 may be a subject of genomic imprinting.
FINDINGS: Using custom-designed aCGH and Sanger sequencing, we have identified a novel de novo 104 kb genomic deletion upstream of FOXF1 in a patient with histopathologically verified full phenotype of ACDMPV. This deletion allowed us to further narrow the FOXF1 enhancer region and identify its critical 15-kb core interval, essential for lung development. This interval harbors binding sites for lung-expressed transcription factors, including GATA3, ESR1, and YY1, and is flanked by the lncRNA genes and CpG islands. Bisulfite sequencing of one of these CpG islands on the non-deleted allele showed that it is predominantly methylated on the maternal chromosome 16.
CONCLUSIONS: Substantial narrowing and bisulfite sequencing of the FOXF1 enhancer region on 16q24.1 provided new insights into its regulatory function and genomic imprinting.

Introduction

Alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV, MIM 265380) is a lethal neonatal developmental lung disorder characterized by reduced number of pulmonary capillaries, muscular thickening in small pulmonary arterioles, and abnormally situated pulmonary veins running alongside pulmonary arterioles [1, 2]. Patients with ACDMPV present with respiratory distress usually accompanied by pulmonary hypertension and often by extra-pulmonary anomalies [3, 4].

In the vast majority of patients with ACDMPV, heterozygous de novo point mutations or genomic deletion copy-number variants (CNVs) of FOXF1 or its distant enhancer region on chromosome 16q24.1 have been identified [4-7]. FOXF1 is a transcription factor involved, among others, in maintaining the endothelial barrier through activation of the S1P/S1PR1 signaling required for the integrity of adherens junctions [8].

An ~60 kb distant tissue-specific enhancer region (chr16:86,212,040-86,271,919; hg19) located 270 kb upstream of FOXF1 has been defined following alignment of ACDMPV causative deletion CNVs that did not include FOXF1 [7]. This region encodes fetal lung-expressed long non-coding RNAs, LINC01081 and LINC01082, and encompasses binding sites for numerous transcriptional regulators, including CEBP/p300, CTCF, and GLI2 [4, 7]. Both LINC01081 and GLI2 have been shown to positively control FOXF1 expression in human fetal lung fibroblasts [7, 9]. Recently, in vivo studies of the mouse syntenic region have shown that it likewise harbors a Foxf1 enhancer [10]. Of note, 30 of 31 genomic deletions pathogenic for ACDMPV, for which parental origin was determined, occurred de novo on the maternal chromosome 16, suggesting genomic imprinting of the FOXF1 locus [4]. Importantly, some of the GLI2-binding sites located in the enhancer region have been found to reside in a partially methylated CpG island, and their function has been shown to be methylation sensitive [7]. Moreover, the putative promoter region of the LINC01081 gene also includes a CpG island that could potentially be involved in its epigenetic regulation.

Here, we present a patient (144.3) manifesting full phenotype of ACDMPV caused by a deletion CNV involving only a portion of the 60-kb enhancer region that enabled us to identify its critical 15-kb core interval.

Patient

The patient was a full-term baby boy, appropriate for gestational age, born via normal spontaneous vaginal delivery with meconium-stained amniotic fluid to a 22-year-old, G2, P2 mother. Pregnancy was uncomplicated. The mother had prenatal care and denied use of tobacco, alcohol, or drugs. Neonatal resuscitation was routine. Birth weight was 3.6 kg. Apgar scores were 8 and 9 at 1 and 5 min of life, respectively.

The patient’s early neonatal course was unremarkable until approximately 8 h of life, when he developed respiratory distress associated with oxygen saturations in the 80’s on room air, prompting admission to the neonatal intensive care unit (NICU). Chest X-ray revealed small bilateral pneumothoraxes and was not consistent with meconium aspiration syndrome. Echocardiogram showed patent foramen ovale with moderate right to left shunting, small patent ductus arteriosus with little flow into the pulmonary artery, mildly dilated right ventricle, mildly dilated right atrium, and severe pulmonary hypertension (3/4 systemic) while on inhaled nitric oxide (iNO) via nasal cannula at 12 h of life.

Upon admission to the NICU, the patient was started on iNO, initially via high flow nasal cannula without significant improvement prompting intubation and mechanical ventilation, first conventional followed by high-frequency oscillatory ventilation (HFOV) at approximately 24 h of life. The patient was transferred to HFOV plus iNO because of worsening hypoxemia complicated by systemic hypotension. Follow-up CXR showed well-expanded lungs and resolution of bilateral pneumothoraxes. The patient did not show significant improvement despite good alveolar recruitment on HFOV, optimization of systemic blood pressure with vasopressor medication, and iNO therapy. At approximately 48 h of life, he was placed on VV extracorporeal membrane oxygenation (ECMO) due to refractory hypoxemic respiratory failure. He remained relatively stable for 4 days on ECMO until he developed a right pneumothorax, which required chest tube placement. On day 7 of the ECMO run, the patient developed a left pneumothorax complicated by large hemothorax, pulmonary hemorrhage, disseminated intravascular coagulation, and tamponade physiology, including severe metabolic/lactic acidosis despite maximal ECMO and vasopressor support. On day 8 of the ECMO run, day 10 of life, the family decided to withdraw support given the patient’s severe clinical deterioration and grim prognosis.

Histopathological evaluation at autopsy confirmed the diagnosis of ACDMPV. The major pathological findings in the lungs included congested pulmonary veins adjacent to pulmonary arteries, thickened alveolar septae with decreased numbers of centrally located capillaries, and arteriolar hypertrophy of lungs.

Material and methods

DNA isolation and sequencing

Blood and FFPE lung samples were obtained after informed consent. DNA had been extracted from peripheral blood using Gentra Purgene Kit (Qiagen, Germantown, MD) and from lung tissue using DNaesy Blood & Tissue Kit (Qiagen). PCR products were treated with ExoSAP-IT (USB, Cleveland, OH) and directly sequenced by the Sanger method. Reference sequences were downloaded from the UCSC Genome Browser (NCBI build 37/hg19, http://genome.ucsc.edu). Sequences were assembled using Sequencher v4.8 (Gene Codes, Ann Arbor, MI).

Array CGH and deletion analysis

Array CGH was done using custom-design 16q24.1 region-specific 4 × 180 K microarrays (Agilent, Santa Clara, CA) according to manufacturer protocol. Deletion junctions were amplified using LA Taq polymerase (Takara Bio., Madison, WI). Parental origin of the deletion-bearing chromosome was determined following identification of informative SNPs and microsatellite polymorphism in a region of parental chromosome 16 corresponding to patient’s deletion.

Bisulfite sequencing

Bisulfite modification of DNA was performed using the EZ DNA Methylation-Lightning Kit (Zymo Research, Irvine, CA). Human Methylated and Non-methylated DNA Set (Zymo Research) was used to assess the efficiency of bisulfite-mediated conversion of DNA. Primers for PCR amplification of bisulfite-treated DNA (updelF: 5′-TTAGTTGGGGTTTATAAATTAGGTATTG-3′ and updelR1: 5′-AAACATTTCAAATAAATCTTTTAATTCC-3′) were designed using a MethPrimer software (http://urogene.org/methprimer/index1.html). PCR was performed in a 25-μL reaction mixture containing 200 ng of bisulfite-treated DNA, and 0.75 units of Taq polymerase (Invitrogen, Carlsbad, CA), applying 30 cycles of the three-step incubation for 30 s at 94 °C, 30 s at 55 °C, and 1 min at 72 °C. The PCR product was purified from unincorporated primers and nucleotides using the MinElute PCR Purification Kit (Qiagen), and T-vector cloned in DH5α cells using the pGEM-T Easy Vector System (Promega, Madison, WI). Plasmid minipreps were prepared from 12 randomly selected transformant colonies using the QIAprep Spin Miniprep Kit (Qiagen) and Sanger sequenced using SP6 universal primer.

Results

Sanger sequencing of the coding portion of FOXF1 did not reveal any single nucleotide or indel variant. Array CGH identified a 104-kb heterozygous deletion CNV upstream of FOXF1, partially overlapping the 60-kb enhancer region (Fig. 1). Sequencing of the PCR-amplified deletion junction showed that the deletion proximal breakpoint maps at chr16:86,149,407 within a simple repeat (CATATA)n and the distal breakpoint maps at chr16:86,253,509 within a unique sequence (Additional file 1: Figure S1). There was no microhomology at the breakpoints. Parental studies revealed that the deletion arose on the maternal chromosome 16 (Additional file 1: Table S1, Figure S2). We did not detect by PCR any evidence of low-level somatic mosaicism in the parental DNA samples from the peripheral blood, indicating that the deletion arose de novo.

Fig. 1

Schematic representation of a protein-coding gene desert-region on 16q24.1 containing the FOXF1 upstream enhancer. a ENCODE and b RefSeq annotations of the region (GRCh37/hg19). c Delineation of the enhancer 15-kb critical interval (black frame) by array CGH. SRO ~60 kb smallest deletion overlap (see Additional file 1: Figure S3)

Comparison of the region deleted in the described patient 144.3 with that deleted in patient 99.3 who was diagnosed with a late onset ACDMPV (chr16:84,764,628-86,238,601) [10] enabled us to define the 15-kb critical enhancer interval chr16:86,238,601-86,253,509. This interval harbors sequences predicted by the encyclopedia of DNA Elements (ENCODE) project to function as transcriptional enhancer (Fig. 1a). It is characterized in the human lung fibroblasts by increased DNase hypersensitivity, significantly increased ratio of histone H3 Lys 4 monomethylation (H3K4Me1, a typical marker of active transcriptional enhancers) compared with trimethylation (H3K4Ma3, typical for promoters), and the presence of histone acetylation H3K27Ac (typical for active enhancers) (Fig. 1b). In addition to harboring the CTCF binding sites, the identified 15-kb region contains also the clustered binding sites for multiple transcription factors expressed in the lung (BioGPS, http://biogps.org), including GATA3, ESR1, GABPA, YY1, SMC3, RAD21, MYC, MAX, and SPI1 that might explain its function as a positive regulator of transcription (Fig. 1b).

The 15-kb interval does not encompass clearly defined CpG islands. However, it is possible that it harbors the CpG island-free differential methylation region (DMR) for the locus. Nonetheless, this region neighbors a partially methylated CpG island overlapping the GLI2-binding sites that have been shown previously to regulate in vitro expression of FOXF1 [7]. We have bisulfite sequenced this CpG island in the lung DNA from patients 144.3 and 60.4 with the FOXF1 upstream enhancer region deleted on the maternal chromosome 16 [7] from two normal lung samples (Additional file 1: Figure S3). Interestingly, we have found that although the methylation of this CpG island is variable in the patient and normal lungs, the extent of methylation depends on the parental origin of chromosome 16 with 4 of 11 CpG sites analyzed being preferentially methylated on the maternal allele overlapping the GLI2-binding sites.

Discussion

Using customized region-specific high-resolution array CGH, we have identified a functionally essential 15-kb core interval in the FOXF1 upstream enhancer region. In fetal lung fibroblasts, this interval features histone modifications typically found in active enhancers and contains sites for binding of numerous transcription factors. In addition to binding CTCF, which can mediate long-range chromatin interactions, of note are the binding sites for GATA3, ESR1, and YY1. GATA3 is a pioneer transcription factor recruiting SWI/SNF chromatin remodeling complex. It is essential for chromatin modification that makes it accessible for ESR1 and other transcription factors [11]. Interestingly, ESR1 has been found to be involved in fetal lung development [12] and mediation of long-range chromatin looping that can position enhancer-bound transcription factors in the proximity to their target promoter [13]. YY1 is a multifunctional transcription factor of the Polycomb family also required during lung morphogenesis. It is expressed in lung mesenchyme [14] as well as in epithelium where it targets SHH expression known to regulate FOXF1 expression.

The deletion in patient 144.3 occurred on maternal chromosome 16, similarly to 30 of 31 other deletions pathogenic for ACDMPV in this region [4] (Additional file 1: Figure S3), further indicating that the FOXF1 locus on 16q24.1 is imprinted. However, the 15-kb core interval does not contain any well-defined CpG island, and other chromatin modifications such as histone methylation or acetylation can contribute to genomic imprinting of this genomic region.

We have elected to bisulfite sequence the CpG island overlapping the GLI2-binding sites located proximally to the 15-kb interval that has been shown to be partially methylated [7]. We found that the extent of methylation of this CpG island was variable but overall higher on maternal chromosome 16, with four out of 11 CpG dinucleotides being preferentially maternally methylated. Interestingly, a small maternal DMR involving the Mcts2 retrogene mapping in an intron of the multi-exonic host HM13 gene in mice has been shown to regulate HM13 expression in a parent-of-origin manner, demonstrating that discrete regions can bring about imprinting [15]. This finding supports a model of partial maternal imprinting of the FOXF1 locus where loss of its paternal copy is embryonic lethal and loss of the maternal copy results in ACDMPV [4]. However, most recently, no evidence of differential methylation was found in the FOXF1 locus using Illumina Infinium HumanMethylation450 BeadChip Array analysis [16], indicating that other epigenetic mechanism can be responsible for genomic imprinting of this locus.

The reported deletion does not include the lncRNA LINC01081 gene, which we have shown to positively regulate FOXF1 expression in vitro [10], suggesting that LINC01081 may be less critically involved in FOXF1 regulation in developing lungs than previously thought. Alternatively, the described 15-kb region may regulate the expression of LINC01081 or some of its shorter isoforms (TCONS_00024760-3, TCONS_00025081, 2, 4, 5), or eRNAs.

We conclude that the described 15-kb sequence located between LINC01082 and LINC01081 encompasses the enhancer interval essential for regulation of the expression of FOXF1 in the fetal lungs that functions likely as a scaffold for transcription factors and mediator of chromatin looping juxtaposing these factors, the FOXF1 promotor, and/or the lncRNA genes. The putative imprinting center for the FOXF1 locus on chromosome 16q24.1 may be located either more centromeric (e.g., in the nearby CpG island with GLI2-binding sites), telomeric (e.g., in the CpG island overlapping with putative promoter of LINC01081), or within this interval but not involving the CpG island. Alternatively, mechanism(s) other than CpG methylation can be responsible for the observed genomic imprinting. High-resolution approaches, e.g., targeted DNA methylation analysis by next generation sequencing (methyl-Seq), can help to unravel the molecular bases of this phenomenon.